MASI Stock Recent News
MASI LATEST HEADLINES
Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results.
Masimo Corporation (NASDAQ:MASI ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Eli Kammerman - VP of Business Development & IR Joe Kiani - Chairman & CEO Micah Young - EVP & CFO Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to Masimo's Second Quarter 2024 Earnings Conference call. The company's press release is available at www.masimo.com.
Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Masimo (MASI) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.62 per share a year ago.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Results: Consolidated revenue was $496.3 million, comprised of healthcare revenue of $343.9 million and non-healthcare revenue of $152.4 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 58,600. Consolidated GAAP operating income was $28.3 million. Consolid.
A Media Snippet accompanying this announcement is available by clicking on this link. ORLANDO, Fla.
NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Masimo Corporation (“Masimo”) (NASDAQ: MASI) for potential violations of the federal securities laws.
After taking a backseat in the first half, the healthcare sector is finally coming to life. The rising odds of a Trump presidency have improved prospects for the industry, validating the case for increasing positions in healthcare stocks to buy now.
Masimo's (MASI) R&D activities raise optimism about the stock.
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public.